Bronkopulmoner Displazi Tanısı, Yönetimi ve Koruyucu Aşılamalar
Özet
Bronkopulmoner displazi (BPD), prematüre bebeklerde görülen kronik bir akciğer hastalığıdır ve özellikle çok düşük gestasyon haftasında doğan bebeklerde önemli morbidite ve mortalite nedenlerinden biridir. Hastalık, akciğer gelişiminin bozulması ve prematüre akciğerin ventilasyon, oksijen toksisitesi ve enfeksiyon gibi etkenlerle hasar görmesi sonucu ortaya çıkar. Klinik olarak doğum sonrası 28. gün veya 36. postmenstrüel haftada oksijen ve/veya solunum desteği ihtiyacının devam etmesi ile tanımlanır. Güncel Jensen sınıflamasında hastalığın şiddeti, kullanılan solunum desteğine göre belirlenmektedir. Bronkopulmoner displazi gelişiminde intrauterin büyüme geriliği, maternal sigara kullanımı, prematüre doğum, mekanik ventilasyon, oksijen toksisitesi ve postnatal enfeksiyonlar önemli risk faktörleridir. Patofizyolojide alveoler gelişim bozukluğu, inflamasyon ve pulmoner vasküler değişiklikler ön plandadır. Klinik bulgular arasında takipne, çekilmeler, wheezing ve uzun süreli oksijen ihtiyacı bulunur. Tedavide temel amaç yeterli oksijenlenmeyi sağlarken ek akciğer hasarını önlemektir. Beslenme desteği, noninvaziv ventilasyon yöntemleri, dikkatli oksijen tedavisi, gerektiğinde mekanik ventilasyon ve seçilmiş olgularda diüretik, bronkodilatör veya glukokortikoid kullanımı uygulanabilir. Ayrıca pulmoner hipertansiyon ve nörogelişimsel sorunlar açısından düzenli izlem önerilir. Prematüre bebeklerde rutin aşılamalar, influenza, COVID-19 ve RSV profilaksisi büyük önem taşımaktadır.
Bronchopulmonary dysplasia (BPD) is a chronic lung disease primarily affecting premature infants and is a major cause of morbidity and mortality, especially in extremely preterm neonates. The disease develops as a result of impaired lung development and injury caused by factors such as mechanical ventilation, oxygen toxicity, and infections. Clinically, BPD is defined by the ongoing need for supplemental oxygen and/or respiratory support at 28 days after birth or at 36 weeks postmenstrual age. The current Jensen classification determines disease severity according to the type of respiratory support required. Major risk factors for BPD include intrauterine growth restriction, maternal smoking, prematurity, prolonged mechanical ventilation, oxygen toxicity, and postnatal infections. The pathophysiology involves disrupted alveolar development, inflammation, and abnormal pulmonary vascular growth. Common clinical findings include tachypnea, chest retractions, wheezing, and prolonged oxygen dependency. The primary goal of treatment is to maintain adequate oxygenation while minimizing further lung injury. Management includes nutritional support, noninvasive respiratory support, careful oxygen therapy, and, when necessary, mechanical ventilation. Selected patients may benefit from diuretics, bronchodilators, or glucocorticoids. Long-term follow-up is essential because of risks such as pulmonary hypertension and neurodevelopmental impairment. Preventive strategies, including routine immunizations and protection against influenza, COVID-19, and respiratory syncytial virus (RSV), are also critically important in premature infants.
Referanslar
Jensen EA, Dysart K, Gantz MG, et al. The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. Am J Respir Crit Care Med 2019; 200:751.
Poindexter BB, Feng R, Schmidt B, et al. Comparisons and Limitations of Current Definitions of Bronchopulmonary Dysplasia for the Prematurity and Respiratory Outcomes Program. Ann Am Thorac Soc 2015; 12:1822.
Beam KS, Aliaga S, Ahlfeld SK, et al. A systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants. J Perinatol 2014; 34:705.
Jensen EA, Edwards EM, Greenberg LT, et al. Severity of Bronchopulmonary Dysplasia Among Very Preterm Infants in the United States. Pediatrics 2021; 148.
Maitre NL, Ballard RA, Ellenberg JH, et al. Respiratory consequences of prematurity: evolution of a diagnosis and development of a comprehensive approach. J Perinatol 2015; 35:313.
Higgins RD, Jobe AH, Koso-Thomas M, et al. Bronchopulmonary Dysplasia: Executive Summary of a Workshop. J Pediatr 2018; 197:300.
Kim F, Bateman DA, Goldshtrom N, et al. Revisiting the definition of bronchopulmonary dysplasia in premature infants at a single center quaternary neonatal intensive care unit. J Perinatol 2021; 41:756.
Wang X, Lu YK, Wu YY, et al. Comparison of two novel diagnostic criteria for bronchopulmonary dysplasia in predicting adverse outcomes of preterm infants: a retrospective cohort study. BMC Pulm Med 2023; 23:308.
Stoll BJ, Hansen NI, Bell EF, et al. Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA 2015; 314:1039.
Nakashima T, Inoue H, Sakemi Y, et al. Trends in Bronchopulmonary Dysplasia Among Extremely Preterm Infants in Japan, 2003-2016. J Pediatr 2021; 230:119.
Romijn M, Dhiman P, Finken MJJ, et al. Prediction Models for Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta-Analysis. J Pediatr 2023; 258:113370.
Kwok TC, Batey N, Luu KL, et al. Bronchopulmonary dysplasia prediction models: a systematic review and meta-analysis with validation. Pediatr Res 2023; 94:43.
Jain VG, Parikh NA, Rysavy MA, et al. Histological Chorioamnionitis Increases the Risk of Bronchopulmonary Dysplasia. Am J Respir Crit Care Med 2024; 209:1272.
Shepherd EG, Clouse BJ, Hasenstab KA, et al. Infant Pulmonary Function Testing and Phenotypes in Severe Bronchopulmonary Dysplasia. Pediatrics 2018; 141.
Taha A, Akangire G, Noel-Macdonnell J, et al. The impact of early tracheostomy on neurodevelopmental outcomes of infants with severe bronchopulmonary dysplasia exposed to postnatal corticosteroids. J Perinatol 2024; 44:979.
Stewart AL, Brion LP. Routine use of diuretics in very-low birth-weight infants in the absence of supporting evidence. J Perinatol 2011; 31:633.
Nelin TD, Lorch S, Jensen EA, et al. The association between diuretic class exposures and enteral electrolyte use in infants developing grade 2 or 3 bronchopulmonary dysplasia in United States children's hospitals. J Perinatol 2021; 41:779.
Bamat NA, Nelin TD, Eichenwald EC, et al. Loop Diuretics in Severe Bronchopulmonary Dysplasia: Cumulative Use and Associations with Mortality and Age at Discharge. J Pediatr 2021; 231:43.
Clouse BJ, Jadcherla SR, Slaughter JL. Systematic Review of Inhaled Bronchodilator and Corticosteroid Therapies in Infants with Bronchopulmonary Dysplasia: Implications and Future Directions. PLoS One 2016; 11: e0148188.
Guaman MC, Pishevar N, Abman SH, et al. Invasive mechanical ventilation at 36 weeks post-menstrual age, adverse outcomes with a comparison of recent definitions of bronchopulmonary dysplasia. J Perinatol 2021; 41:1936.
Brumer E, Shabanova V, Urbach H, et al. Bronchopulmonary Dysplasia in the First Year: Insights Into Severity, Medication Use, and Healthcare Utilization. Pediatr Pulmonol 2025; 60: e71254.
Caserta MT, O'Leary ST, Munoz FM, Ralston SL; Commıttee On Infectious Diseases. Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection.Pediatrics. 2023 Jul 1;152(1):e2023061803. doi: 10.1542/peds.2023-061803.
Ralston SL, Lieberthal AS, Meissner HC, et al. Sayles S 3rd, Hernandez-Cancio S; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474-502. doi: 10.1542/peds.2014-2742. Erratum in: Pediatrics. 2015 Oct;136(4):782. doi: 10.1542/peds.2015-2862.
https://turkpedkar.org.tr/wp-content/uploads/2023/03/PALIVIZUMAB-PROFLAKSI-REHBERI-27.03.2023.son_.pdf (son erişim: 20.01.2025).
https://neonatology.org.tr/tani-tedavi-protokolleri (son erişim: 20.01.2025).
American Academy of Pediatrics. [Immunization in Special Clinical Circumstances Immunization in Preterm and Low Birth Weight Infants] In: Kimberlin DW, Banerjee R, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2024 Report of the Committee on Infectious Diseases. American Academy of Pediatrics; 2024: 87-88.
